Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH NIAID

Contract Value

Not provided

Codes & Classification
Solicitation Number

BAA-75N93026R00008

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

AN12

Additional Details
Set Aside

None

Place of Performance

UNITED STATES

SourceSAM
Documents3
The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), has issued a Broad Agency Announcement (BAA) under solicitation number BAA-75N93026R00008, titled "Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB)." This active solicitation seeks to engage qualified organizations in advanced research and development activities aimed at elucidating the immune mechanisms that confer protection against Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). The primary objective of this procurement is to support the establishment and operation of a research center dedicated to investigating the immunological factors and pathways that underlie protective responses to M. tuberculosis infection. The intended outcome is to generate foundational knowledge that can inform the development of novel vaccines, therapeutics, and diagnostic tools for TB, a disease of significant global health concern. The scope of work likely encompasses multidisciplinary research efforts, including but not limited to immunological assays, animal model studies, and translational research activities that bridge basic science and clinical application. Key requirements for this opportunity include demonstrated expertise in research and development within the physical, engineering, and life sciences, as classified under NAICS code 541715. While the NAICS description specifically excludes nanotechnology and biotechnology, the focus remains on advanced scientific inquiry relevant to immunology and infectious diseases. Offerors are expected to propose comprehensive research strategies, robust project management plans, and clear deliverables that align with the overarching goals of the IMPAc-TB initiative. The place of performance for this contract is within the United States. The procurement is managed by the NIH NIAID Office, under the Department of Health and Human Services. Interested parties should note that the solicitation has undergone at least two amendments, both of which provide responses to questions from potential offerors, indicating an active dialogue and clarification process to ensure a clear understanding of the solicitation requirements. The solicitation is classified under Product Service Code AN12, which pertains to research and development in the area of medical and health sciences. The opportunity is open to eligible entities capable of fulfilling the scientific and administrative demands of a high-impact research center. For further information or to submit inquiries, potential offerors may contact the primary point of contact, Chris Ray, at [email protected] or 240-627-3365, and the secondary contact, Robert Corno, at [email protected] or 240-669-5151. The solicitation and its amendments, along with additional attachments, are available for review on the official SAM.gov opportunity page. Responses to this solicitation are due by September 1, 2026. Interested organizations are encouraged to review the full solicitation and associated amendments to ensure compliance with all requirements and to assess alignment with their organizational capabilities and research interests. This opportunity represents a significant investment in advancing the scientific understanding of TB immunity, with the potential to impact public health outcomes on a global scale. Contractors with a strong track record in immunological research and a commitment to collaborative, multidisciplinary science are well-positioned to contribute to the success of the IMPAc-TB Center.